BriaCell Therapeutics BCTX 2021 Cancer Immunotherapy Investor Presentation

BriaCell Therapeutics presents an overview of its cancer immunotherapy pipeline and clinical development strategy. The presentation outlines the company's capitalization structure, including Nasdaq and TSXV listings, cash position of approximately $60M, and market capitalization of $87.6M as of June 2021. Forward-looking statements address development timelines, regulatory pathways, and capital requirements for advancing its therapeutic programs.